We previously developed methods for establishing CD8 regulatory T cell (Treg) clones from normal human peripheral blood and demonstrated that these clones were capable of killing T cell receptor (TCR)-activated autologous CD4 T cells. Based on phenotypic and functional characterization of the CD8 Treg clones, we have identified a corresponding population of endogenous CD8 Treg in normal human peripheral blood. These cells appear morphologically as large lymphocytes with abundant cytoplasm and have the following unique phenotype: CD3
Introduction
Immune responses are controlled by various populations of T cells with regulatory function. These regulatory T cells (Treg) suppress activated immune cells thereby maintaining immune system homeostasis and self-tolerance [1, 2, 3, 4, 5, 6, 7] . Although the phenotype and function of CD4 Treg have been characterized in great detail, CD8 Treg have not been well characterized. In murine models, CD8 Treg contribute to resistance to experimental allergic encephalomyelitis (EAE), a model for human multiple sclerosis [8, 9] . Adoptive transfer of CD122 +
CD8
+ T cells prevents development of abnormal T cells in CD122-deficient mice [10] . More recent studies have shown that CD8 Treg suppress pathogenic autoreactive CD4 T cells via a Qa-1-restricted pathway [11] . Genetic disruption of the inhibitory interaction between these CD8 T cells and their target Qa-1-expressing CD4 T cells results in increased susceptibility to EAE [11, 12] and development of a lethal systemic-lupus-erythematosus-like autoimmune disease [13] . CD8 Treg have also been identified in patients with multiple sclerosis [14] , ovarian carcinoma [15] and HIV-infection [16] . [10] , and CD8 + CCR7 + CD45RO + IL10 + [15] . It is not clear whether different CD8 Treg subsets represent independent populations or whether they reflect different characteristics of a single population. However, one consistent functional feature of CD8 Treg is that these cells act primarily through suppression of activated CD4 T cells [10, 11, 20, 21] . Moreover, almost all studies on CD8 Treg have been conducted in murine models and few studies have focused on CD8 Treg in humans.
Our limited understanding of CD8 Treg populations and the inherent uncertainty of extrapolating from mouse models to humans led us to develop a novel protocol to establish stable CD8 T cell clones with auto-regulatory activity from normal human peripheral blood [22] . CD8 Treg clones effectively suppressed activated CD4 T cells and expressed a variety of TCR Vb chains, indicating that the CD8 Treg population in humans is polyclonal. Suppression by CD8 Treg clones was cell contact-dependent, involved CD11a/CD18 (LFA-1) and CD8 surface antigens and resulted in lysis of CD4 + target T cells. Moreover, suppression by CD8 Treg was independent of the antigen-specificity of CD4 + target T cells and HLA compatibility between effector and target cells [22] . CD8 Treg clones were CD8ab + TCRab + TCRcd 2 TCRVa24 2 TCRVb11 2 and did not expressed significant levels of CD28, CD103, CD122, CCR7 and IL-10. Unlike CD4 Treg, which are largely defined by the expression of Foxp3 [1, 23, 24] , levels of Foxp3 expression in CD8 Treg clones were not correlated with their suppressive activity [22] . The lack of CD28, CD103, CD122, CXCR4 and CCR7 expression and dissociation of Foxp3 expression from suppressive activity indicate that CD8 Treg clones are different from the CD103 + , CD28 
IL10
+ CD8 Treg subsets previously reported. Interestingly, CD8 Treg clones frequently expressed CD56 and rarely expressed CD161 [22] , even though CD56 and CD161 are often co-expressed on NK and NKT cells [25, 26] .
The establishment of stable human CD8 Treg clones has provided us with a consistent experimental system to characterize human CD8 Treg in vitro and to identify phenotypic characteristics that can be used to define the corresponding endogenous population in vivo. In the present study, we describe a population of CD3
2 T cells in normal human peripheral blood that function as CD8 Treg. Like CD8 Treg clones, these CD8 Treg kill TCR-activated CD4 T cells independent of the antigen-specificity of CD4 target T cells and HLA compatibility between effector and target cells.
Results

Presence of CD3
+ CD161 2 CD56 + CD8 T Cell Subset in Normal PBMC CD56 and CD161 are natural killer (NK) cell and natural killer T (NKT) cell surface markers [1, 22, 23, 24, 25, 26] , which are often co-expressed. In contrast, Va24 and Vb11 are characteristic cell surface markers for NKT cells [27, 28, 29] Figure 1A ). The percentage of this population varied widely from 0.2% to 31.3% of all CD8
+ T cells with a median of 3.2% and mean of 6.8%. Seventeen of the 22 donors had less than 10% CD8 T cells that were CD161 2 CD56 + ( Figure 1B ). Since these were anonymous donor samples, we were not able to examine whether the variable frequency of CD161 (Figure 2 and 3 ), but the level of CD62L expression level was significantly lower in CD8 Treg compared to CD8 Tcon (Figure 3 ). CD27, a member of the tumor necrosis factor receptor (TNFR) superfamily, is expressed on the majority of CD4 and CD8 T cells, especially naïve T cells [30] . In our analysis, CD27 was highly expressed on CD8 Tcon, however, most CD8 Treg cells were CD27 negative or low. Figure 5A and 5B). After in vitro expansion, both CD56 pos cells and CD56 neg populations lost expression of CD45RA and became strongly CD45RO positive. It has been reported that activation of T cells via TCR/CD3 induces high surface expression of CD27 [30] . However, the expression of CD27 in CD8 Treg (CD56 pos ) cells remained low ( Figure 5A and 5B).
Lysis of Activated Allogeneic and Autologous CD4
+ T Cells by CD8
We have previously shown that human CD8 Treg-mediated suppression requires TCR activation of CD4 + target T cells but is independent of the antigen-specificity of CD4 + target T cells and HLA compatibility between effector and target cells [22] . To determine whether polyclonal CD8 Treg (CD56 pos ) cells had similar functional activity, CD8
2 T cells were FACS-purified, expanded in vitro for 7-10 days and tested for cytolytic activity against an allogeneic Epstein-Barr virus (EBV)-specific CD4 T cell clone (S2B5) we previously established and used as target cells for CD8 Treg clones [22] . Activated CD8 Treg (CD56 pos ) lysed the CD4 + target cell clone (S2B5), but only after target cells were sensitized through TCR activation with anti-CD3 monoclonal antibody. In contrast, activated CD8 Tcon (CD56 neg ) cells had no specific lytic activity in this assay, either with or without TCR activation of the CD4 + target cells ( Figure 6A ). To further examine their functional activity, CD8 Treg (CD56 pos ), CD8 Tcon (CD56 neg ), and 
CD161
2 CD56 + T cell subset in normal PBMC corresponds to an endogenous population of CD8 Treg.
Discussion
In previous studies we established a panel of human CD8 Treg clones that selectively suppress activated CD4 T cells in vitro [22] . Here we sought to identify and characterize a population of CD8 T cells in normal human peripheral blood that had similar functional activity. Based on phenotypic and functional characterization of the CD8 Treg clones, we identified a population of 
CD56
+ CD8 T cells. PBMC isolated from healthy donors were stained and analyzed as described in Materials and Methods. Intensity of cell surface expression of various markers shown in each graph is compared for different CD3 The selection of CD3, CD8, CD56 and CD161 as potential positive and negative markers of peripheral CD8 Treg was based on the detailed phenotypic characterization of CD8 Treg and nonTreg clones we had previously established. Since both sets of clones were established in a similar method and differed primarily by their ability to suppress autologous activated CD4 T cells, we reasoned that the phenotypic comparison of these clones would identify surface markers that could distinguish CD8 Treg from conventional CD8 T cells in normal peripheral blood. When this marker set was subsequently tested in 22 necessary to define the cellular requirements for CD8 Treg activity in vivo. We used cell surface expression of CD56 without concomitant expression of CD161 as the primary identifying feature of this novel CD8 T cell subset. CD56 is a cell surface marker characteristic of all human NK cells and 90% of NK cells also express CD161 [31] . Conventional NK cells do not express CD3 and TCR but some of these cells express CD8aa homodimers [32] . In mice, NKT cells were described as a subset of T cells in thymus that expressed NK-associated cell surface antigen NK1.1 (CD161 in human) [33] . In humans, NKT cells are a heterogeneous group of cells that possess properties of both T cells and NK cells [34, 35] . NKT cells characteristically express CD3 and CD161; most NKT cells express CD4 and few express CD8. Only some NKT cells express CD56 and expression of CD56 is therefore not a distinguishing marker for these cells. In contrast to conventional T cells, NKT cells specifically recognize lipid antigens presented by CD1d molecules. NKT cells typically produce IFN-c, IL-4 and other cytokines upon activation and are not directly cytolytic. Classical NKT cells (also termed invariant NKT), which constitute more than 80% of NKT cells, express a canonical Va14-Ja18 a chain with a variable Vb8, 27, or 22 b chain in mouse or Va24-Ja18/Vb11 in human. Non-classical NKT cells in the mouse express a variety of rare but recurrent, CD1d-reactive Va3.2-Ja9/Vb8, Va8/Vb8, and other TCRs [28, 29] . In contrast to both conventional NK and NKT cells, the CD8 Treg we identified in human peripheral blood express CD3, CD8ab, TCRab and CD56 but not CD161, Va24 or Vb11 (data not shown). CD8 Treg are highly lytic towards activated CD4 T cells regardless of HLA compatibility. Finally, CD8 Treg do not secrete high levels of IL-4 upon CD3 activation though the production of IFN-c is greatly enhanced [22] The low or negative expression of CD27 on CD8 Treg cells may be functionally related. CD27 is a member of the TNFreceptor superfamily that is expressed on early thymocytes and naïve T cells. All CD4
2 T cells [30] and most NK cells express CD27 [39] . CD70, a unique ligand for CD27 is transiently expressed on activated T cells, B cells and dendritic cells. The CD27 receptor activates the NF-kB and JNK pathways [40] and plays a critical role in B cell activation and differentiation. On conventional T cells, CD27 expression is increased after activation, but is subsequently downregulated as T cells undergo proliferation and acquire effector cell function. An inverse correlation between expression of CD27 and cytotoxic effector function has been reported in both CD8 T cells and NK cells [41, 42] . Our analysis of conventional naïve CD8 T cells confirmed that these cells express CD27 and this was maintained during short term activation in vitro. In contrast, very few freshly isolated CD8 Treg expressed CD27 even though more than 90% of these cells are CD45RA + CD45RO 2 . Moreover, CD27 expression on CD8 Treg after PHA activation remained significantly lower than on conventional CD8 T cells. These observations suggest that CD8 Treg may be intrinsically primed toward cytolytic function.
Having identified a phenotypically and functionally distinct population of human CD8 Treg in normal peripheral blood, further studies are needed to define the role of these cells in the regulation of T cell responses and the molecular mechanisms that mediate their function. The ability of CD8 Treg to selectively lyse activated CD4 T cells appears to be a distinct functional program that is not shared by other cytolytic cells including NK cells and conventional cytolytic CD8 T cells. Although these cells express CD8 and TCR, the specificity of these cells is not restricted by expression of identical MHC class I molecules on the target cell surface. Thus the mechanisms used by these cells to selectively recognize and interact with activated CD4 + T cells have not been defined. Identification of these interacting structures will be needed to establish the mechanisms by which these cells can regulate immune responses in vivo. Similarly, the derivation of these cells and their relationship to conventional CD8 T cells is also an important area for further investigation. However, the identification of a distinct population of CD8 T cells with the ability to selectively regulate activated CD4 T cells is a critical step in the functional characterization of these cells and will also allow the characterization of these cells in different clinical conditions.
Materials and Methods
Antibodies
Monoclonal antibodies (mAb) for CD3, CD8a, CD8b, CD25, CD56, CD62L, CD69, CD94, CD161, Va24, Vb11 and NKG2a cell surface staining were obtained from Beckman Coulter (Brea, CA). Additional mAbs for CD3, CD8a, CD27, CD28, CD45RA, CD45RO, CD56, CD62L, CD94, CD127 and CD161 were purchased from Biolegend (San Diego, CA). Mouse anti-human CD3 IgE mAb (RDI-M1654clb) was purchased from Research Diagnostics Inc (Flanders, NJ). Purified mouse IgE mAb was purchased from Biolegend (San Diego, CA).
Cells and Culture
Normal PBMC were isolated from donor leukopack samples provided by the Dana-Farber Cancer Institute Blood Donor Center after Ficoll-Paque (Amersham Pharmacia Biotech) separation. Normal PBMC were also isolated from blood samples from healthy subjects after written consent, which was approved by the institutional review board of the Brigham and Women's hospital.
EBV-transformed B cell lines (LCL) were maintained in RPMI 1640 (Mediatech, Inc) supplemented with 10% heat-inactivated FBS, 2 mM glutamine, 1 mM sodium pyruvate, 10 mM Hepes, 50 I U/ml penicillin and 50 mg/ml streptomycin. T cell clones or lines were maintained and expanded via stimulation with PHA. Briefly, T cells were first stimulated with 1.2 mg/ml PHA (PHA-L, Sigma) in Iscove's Modified Dulbecco's Medium (IMDM-Invitrogen) supplemented with 10% heat-inactivated human AB serum (FBS for S2B5 cells), 100 u/ml recombinant human IL-2 (rIL-2), 50 I.U/ml penicillin and 50 mg/ml streptomycin (complete IMDM) in the presence of irradiated PBMC (3,500 cGy, 1610 6 or 3610 6 cells/well) and LCL (6,000 cGy, 2610 5 or 6610 5 cells/ well) as feeder cells in 24-well plates. Culture medium (complete IMDM with rIL-2) was changed every 2 to 3 days.
Flow Cytometric Analysis of Cell Surface Antigen Expression
To characterize human peripheral blood, PBMC were labeled with FITC-conjugated aCD3, PC7-conjugated aCD8, PE-conjugated aCD161 and PC5-conjugated aCD56 followed by FACS analysis with a BD FACSCanto II (Figure 1) . To analyze the cell surface antigen expression profile of CD3
+ cells, PBMC were labeled with Brilliant Violet 605 TM -conjugated aCD3, Pacific Blue TM -conjugated aCD8, PC5-conjugated aCD56, Alexa FluorH 647-conjugated aCD161, PC7-conjugated aCD45RA, FITC-conjugated aCD27, aCD127 or aCD94 and PE-conjugated aCD25, aCD45RO, aCD62L, aCD69 or aNKG2a followed by FACS analysis with a BD LSR II flow cytometer (Figure 2 and 3) . To analyze the cell surface antigen expression profile of isolated CD8 T cell subsets after PHA stimulation, cells were labeled with FITC-conjugated aCD3, PC7-conjugated aCD8, PC5-conjugated aCD56 and PE-conjugated aCD27, aCD45RA, aCD45RO, aCD62L, aCD94, aCD161, aNKG2a or aVa24 followed by FACS analysis with a BD FACSCanto II ( Figure 5 ).
Isolation of CD8 Treg from PBMC
PBMC were labeled with FITC-conjugated aCD3, PC7-conjugated aCD8, PE-conjugated aCD161 and PC5-conjugated aCD56. pos cells was stained with PE-conjugated aCD8b or aVa24 followed by FACS analysis with a BD FACSCanto II ( Figure 4B ). Isolated CD56 pos and CD56 neg cells were stimulated with 1.2 mg/ml PHA in complete IMDM with human AB serum in the presence of feeder cells and rIL-2 (100 u/ml) in 24-well plates as described above. Culture medium (complete IMDM with rIL-2) was changed every 2 to 3 days, or when media turned yellow. Cells were cultured for 7-15 days before being analyzed for suppressive activity.
Wright-Giemsa Stain
Cells isolated from PBMC were suspended in complete IMDM at a concentration of 1610 5 cells/ml or lower. Cells (100 ml per slide) were mounted onto slides through cytospin. After drying overnight, cells were stained with Wright-Giemsa reagents. Staining was visualized using a bright-field microscope (Leica DC300).
CD8 Treg Suppressive Activity Assay (CytoTx Flow assay)
Assays were performed and interpreted as described previously [22] . Briefly, CD4 T cells (target) and CD8 T cells (effector) were /ml) were then incubated for 3 hr at 37uC in the presence or absence (as control) of aCD3 IgE (1 mg/ml) in a tissue culture incubator. In some experiments, purified mouse IgE antibody (1 mg/ml) was used as isotype control for aCD3 IgE to treat target cells. After extensive washing, target cells (1-3610 5 ) were mixed with effector cells in a U-bottomed 96-well plate at various E/T ratios. After 4 hr of incubation at 37uC under 5% CO 2 , cells were harvested and analyzed by flow cytometry. Percent cytotoxicity was calculated as follows: 1006(% of total apoptotic target cells -% of spontaneous apoptotic target cells)/(100 2 % of spontaneous apoptotic target cells).
Statistical Analysis
Data are expressed as mean6SD. Differences between groups were tested via unpaired two-tailed Student's t-test.
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